How US drug firms plan to hike NHS medicine prices
US health firms are confident it will be easier to gain access to the NHS and hike the price of medicines after Brexit, a document reveals.
The prospectus sets out how pharmaceutical companies will demand new rules that prohibit discrimination against foreign suppliers and end restrictions on the number of suppliers.
Written by the US Chamber of Commerce last month, it notes the failed three-long battle to strike a deal with the EU, which collapsed partly because of fears over opening up public health services.
And, crucially, it states: Concerns about potential impacts on Britain's National Health Service are being aired.
It should prove easier to overcome these challenges with the UK as an individual negotiating partner.
The document, revealed by the Mirror, wa...